Bladder tumor recurrence after primary surgery for transitional cell carcinoma of the upper urinary tract. 2004

S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
Department of Urology, Technical University Dresden, Dresden, Germany. sven.oehlschlaeger@mailbox.tu-dresden.de

OBJECTIVE Primary transitional cell carcinoma (TCC) of the upper urinary tract represents 6-8% of all TCC cases. Nephroureterectomy with removal of a bladder cuff is the treatment of choice. The rates of TCC recurrence in the bladder after primary upper urinary tract surgery described in the literature range between 12.5 and 37.5%. In a retrospective analysis we examined the occurrence of TCC after nephroureterectomy for upper tract TCC in patients without a previous history of bladder TCC at the time of surgery. METHODS Between 1990 and 2002, 29 patients underwent primary nephroureterectomy for upper tract TCC. The mean age of the patients was 69.5 years. In 5 cases upper urinary tract tumors were multilocular, in the remaining cases unilocular in the renal pelvis (n=12) or the ureter (n=12). The follow-up was available for 29 patients with a mean follow-up of 3.37 (0.1-11.2) years. RESULTS 11/29 (37.9%) patients had TCC recurrence with 9/11 patients having bladder TCC diagnosed within 2.5 years (0.9-6.0) after nephroureterectomy. 13/29 patients are alive without TCC recurrence, 3/29 patients died due to systemic TCC progression and 5/29 died of unrelated causes without evidence of TCC recurrence. CONCLUSIONS Our data indicate a high incidence of bladder TCC after nephroureterectomy for primary upper tract TCC of up to 6 years after primary surgery. Because of the high incidence of bladder TCC within the first 3 years of surgery, careful follow-up is needed over at least this period.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
January 1991, European urology,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
August 2020, Translational andrology and urology,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
January 1985, Annales chirurgiae et gynaecologiae,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
October 2003, Cancer,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
July 2001, International journal of urology : official journal of the Japanese Urological Association,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
March 2007, European urology,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
January 2001, Urologia internationalis,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
February 2005, Urology,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
March 1992, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
S Oehlschläger, and A Baldauf, and D Wiessner, and J Gellrich, and O W Hakenberg, and M P Wirth
January 2011, Urologic oncology,
Copied contents to your clipboard!